Modulation of central nitric oxide as a therapeutic strategy for schizophrenia

Klinik Psikofarmakoloji Bulteni

Volumn 20, Issue 2, 2010, Pages 115-119

  MacKay, Marnie ^a,b   Cetin, Mesut ^c   Baker, Glen ^a,b   Dursun, Serdar ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA HOSPITAL EDMONTON   (Canada)

^c GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Nitric oxide; Pharmacotherapy; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ARGININE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ATAXIA; AUTOPSY; CALCIUM BINDING; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPOLARIZATION; DISABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION;

EID: 77957108945     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.1080/10177833.2010.11790644     Document Type: Review

References (34)

1. Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regressaion analysis. BMJ, 321, 1371-1376.
2. Awad, G.A. & Voruganti, L.N.P. The burden of schizophrenia on caregivers: A review. PharmacoEconomics 2008;26:149-62.
3. Cahn, W., Hulshoff -Pol, H.E., Lems, E.B.T.E., van Haren, N.E.M., Schnack, H.G., van der Linden, J.A., Schothorst, P.F., van Engeland, H., & Kahn, R.S. Brain Volume Changes in First-Episode Schizophrenia: A 1-Year Follow-up Study. Arch Gen Psychiatry 2002;59: 1002-1010.
4. Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P., & Croudace, T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review. Arch Gen Psychiatry 2005;62: 975-983. (Pubitemid 41248376)
5. Jarskog, L. F., & Lieberman, J. A. Neuroprotection in schizophrenia. J Clin Psychiatry 2006;67:67.
6. Robinson, D., Woerner, M. G., Alvir, J. M., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., & Lieberman, J. A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56: 241-247. (Pubitemid 29125132)
7. Vauth, R., Loschmann, C., Rusch, N., & Corrigan, P. W. Understanding adherence to neuroleptic treatment in schizophrenia. Psychiatry Res 2004;126:43-49.
8. Perkins, D. O., Johnson, J. L., Hamer, R. M., Zipursky, R. B., Keefe, R. S., Centorrhino, F., et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Res 2006;83: 53-63.
9. Drake, R. J., Dunn, G., Tarrier, N., Bentall, R. P., Haddock, G., & Lewis, S. W. Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. J Clin Psychiatry 2007;68: 81-86. (Pubitemid 46220128)
10. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (Clinical Antipsychotic Trials of Intervention Effectiveness [CATIE] Investigators). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 2005;353:1209-1223
11. Lewis, S. W., Barnes, T. R., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bull 2006;32: 715-723.
12. Paton, C., Whittington, C., & Barnes, T. R. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: A meta-analysis. J Clin Psychopharmacol 2007;27: 198-204. (Pubitemid 46594939)
13. Harrison, P.J., & Owen, M.J. Recent findings and their pathophysiological implications. Lancet 2003;316: 417-9.
14. Bredt, D. S., & Snyder, S. H. Nitric oxide, a novel neuronal messenger. Neuron,1992;8: 3-11.
15. Garthwaite, J., & Boulton, C. L. Nitric oxide signaling in the central nervous system. Ann Rev of Physiol, 1995;57: 683-706.
16. Kiss, J. P., & Vizi, E. S. Nitric oxide: A novel link between synaptic and nonsynaptic transmission. Trends Neurosci, 2001;24: 211-215.
17. Bernstein, H.G., Bogerts, B., & Keilhoff, G. The many faces of nitric oxide in schizophrenia. A review. Schizophr Res, 2005;78:69-86.
18. Brenman, J. E., & Bredt, D. S. Synaptic signaling by nitric oxide. Cur Op Neurobiol 1997;7: 374-378.
19. Akyol, O., Zoroglu, S. S., Armutcu, F., Sahin, S., & Gurel, A. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo, 2004;18: 377-390.
20. Johansson, C., Deveney, A. M., Reif, D., & Jackson, D. M. The neuronal selective nitric oxide inhibitor AR-R 17477, blocks some effects of phencyclidine, while having no observable behavioural effects when given alone. Pharmacol & Toxicolo, 1999;84: 226-233. (Pubitemid 29205284)
21. Johansson, C., Jackson, D. M., & Svensson, L. Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat. Psychopharmacol 1997;31: 167-173.
22. Klamer, D., Engel, J. A., & Svensson, L. The neuronal selective nitric oxide synthase inhibitor, nomega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice. European J Pharmacol 2004:303; 103-107.
23. Bujas-Bobanovic, M., Robertson, H. A., & Dursun, S. M. Effects of nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester on phencyclidine-induced effects in rats. European J Pharmacol 2000;409: 57-65.
24. Bujas-Bobanovic, M., Bird, D.C., Robertson, H., & Dursun, S. M. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol, 2000;130: 1005-1012. (Pubitemid 30453534)
25. Pitsikas, N., Zisopoulou, S., & Sakellaridis, N. Nitric oxide donor molsidomine attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801. J Neurosci Res 2006:84; 299-305.
26. Akbarian, S., Bunney, W.E., Jr, Potkin, S.G., Wigal, S. B., Hagman, J.O., Sandman, C.A., et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arc Gen Psychiatry, 1993;50: 169-177. (Pubitemid 23077471)
27. Lauer, M., Johannes, S., Fritzen, S., Senitz, D., Riederer, P., & Reif, A. Morphological abnormalities in nitric-oxide-synthase-positive striatal interneurons of schizophrenic patients. Neuropsychobiol 2005:52: 111-117.
28. Xing, G., Chavko, M., Zhang, L. X., Yang, S., & Post, R. M. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophrenia Res 2002:58; 21-30. (Pubitemid 35291183)
29. Andreasen, N. C., Rezai, K., Alliger, R., Swayze, V. W.,2nd, Flaum, M., Kirchner, P., et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. assessment with xenon 133 single-photon emission computed tomography and the tower of london. Arch Gen Psychiatry, 1992:49; 943-958.
30. Lewis, D.A., & Levitt, P. Schizophrenia as a disorder of neurodevelopment. Ann Rev Neurosci, 2002;25: 409-432
31. McGlashan, T.H., & Hoffman, R.E. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 2000;57: 637-648.
32. Suzuki, E., Nakaki, T., Nakamura, M., & Miyaoka, H. Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia. J Psychiatry & Neurosci 2003;28:288-292.
33. Ramirez, J., Garnica, R., Boll, M. C., Montes, S., & Rios, C. Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: A pilot study. Schizophrenia Res 2004;68:357-361. (Pubitemid 38526156)
34. Chrapko, W. E., Jurasz, P., Radomski, M. W., Lara, N., Archer, S. L., & Le Melledo, J. M. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004;56: 129-134.